Synonyms: BGB-116673 | BGB116673 | compound 14 [WO2021219070A1]
Compound class:
Synthetic organic
Comment: The chemical structure for catadegbrutinib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as a Bruton tyrosine kinase (BTK) degrader with antineoplastic potential. A structure match in PubChem aligns catadegbrutinib with the company research code BGB-116673/BGB116673, and with a structure claimed in Beigene's patent WO2021219070A1 [1]. BGB116673 is a conjugate of a BTK inhibitor with an E3 ligase ligand. As a PROTAC class degrader the resulting molecule functions to recruit targeted proteins to E3 ubiquitin ligase for proteasomal degradation of wild type and mutated forms of the BTK protein.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Ligand families/groups | PROTACs, molecular glues and other degraders |
International Nonproprietary Names ![]() |
|
INN number | INN |
13463 | catadegbrutinib |
Synonyms ![]() |
BGB-116673 | BGB116673 | compound 14 [WO2021219070A1] |
Database Links ![]() |
|
CAS Registry No. | 2736508-60-2 (source: WHO INN record) |
GtoPdb PubChem SID | 507750369 |
PubChem CID | 166521972 |
Search Google for chemical match using the InChIKey | ZSOLMVZWDSGPDD-SSEXGKCCSA-N |
Search Google for chemicals with the same backbone | ZSOLMVZWDSGPDD |
Search PubMed clinical trials | catadegbrutinib |
Search PubMed titles | catadegbrutinib |
Search PubMed titles/abstracts | catadegbrutinib |
UniChem Compound Search for chemical match using the InChIKey | ZSOLMVZWDSGPDD-SSEXGKCCSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | ZSOLMVZWDSGPDD-SSEXGKCCSA-N |